Neurology

Top articles of the week from The American Journal of Pharmacy Benefits.

Cell structure may allow immune cells to attack myelin in multiple sclerosis.

Another study suggests gut bacteria has an important role in triggering multiple sclerosis.

Targeting specific transportation system across the damaged blood-brain barrier could halt MS disease progression.

Multiple sclerosis researchers actively seek new agents than can promote repair and remyelination.

Experimental drug found to reduce inflammation and promote remyelination in patients with relapsing-remitting multiple sclerosis.

The brain may stop the process of repairing myelin due to a blood clotting protein.

MRI brain scans on children at high risk of multiple sclerosis may indicate earlier diagnoses and treatments.

Exercise found to be one of the most important approaches for self-managing the consequences of multiple sclerosis.

Ozanimod may slow multiple sclerosis progression more than first-line therapy.

Research questions whether reducing sodium intake could reduce the risk of developing multiple sclerosis.

Fingolimod shows 82% efficacy reducing the annualized multiple sclerosis relapse rate.

A look at last week's top stories in the world of pharmacy.

Top news of the week from Specialty Pharmacy Times.

Combination therapy found to reverse multiple sclerosis in mice models.

A look at last week's top stories in the world of pharmacy.

MRIs show brain changes related to multiple sclerosis before symptom onset.

The presence of certain bacteria could result in worsening of multiple sclerosis.

Allergy medication may cause remyelination in humans with multiple sclerosis.

Top news of the week from Specialty Pharmacy Times.

An estimated 75% of patients with multiple sclerosis report fatigue among their most disabling disease symptoms.

A lack of biomarkers can result in a delay in multiple sclerosis diagnosis and treatment.

The grant from the National Multiple Sclerosis Society aims to support the development of a potential oral treatment for progressive forms of MS.

Several drugs are in the pipeline for the treatment of specialty conditions, including cancer and multiple sclerosis.

Top news of the day from across the health care landscape.